¹**Machine learning for predicting severe dengue, Puerto Rico**

2

5
6

8
9

Zachary J. Madewell, PhD^{1,*}; Dania M. Rodriguez, PhD¹; Maile B. Thayer, PhD¹; Vanessa Rivera-Amill,
4. PhD²: Gabriela Paz-Bailey, MD. PhD^{1,} Laura E. Adams. DVM^{1,} Joshua M. Wong. MD¹ 4 PhD²; Gabriela Paz-Bailey, MD, PhD¹; Laura E. Adams, DVM¹; Joshua M. Wong, MD¹

 $\frac{1}{2}$ Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, San Juan, Puerto Rico.

² Ponce Health Sciences University/Ponce Research Institute, Ponce Puerto Rico. ² Ponce Health Sciences University/Ponce Research Institute, Ponce, Puerto Rico.

⁹* Correspondence to: Zachary J. Madewell, PhD; ock0@cdc.gov

Abstract

- ³⁶**Conclusions:** ML models, especially gradient boosting algorithms, outperformed traditional warning
- 37 signs in predicting severe dengue. Integrating these models into clinical decision-support tools could help
- 38 clinicians better identify high-risk patients, guiding timely interventions like hospitalization, closer
- ³⁹monitoring, or the administration of intravenous fluids. The subanalysis excluding hemoconcentration
- ⁴⁰confirmed the models' applicability in resource-limited settings, where access to laboratory data may be
- 41 limited.
- ⁴²**Keywords:** ensemble learning, gradient boosting, feature importance, clinical decision support,
- ⁴³Caribbean

⁴⁴**Background**

⁴⁵Dengue is a significant public health concern worldwide, with approximately 390 million ⁴⁶infections annually, of which 96 million manifest clinically [1, 2]. In Puerto Rico, dengue has been 47 associated with nearly 30,000 confirmed and probable cases from 2010 to 2020, including 584 severe 48 cases, 10,000 hospitalizations, and 68 deaths [3]. A surge in dengue cases on the island in 2024 prompted ⁴⁹a public health emergency declaration by Puerto Rico's Department of Health, highlighting the ongoing 50 threat of dengue to the island [4]. These regular outbreaks strain healthcare resources and pose substantial ⁵¹morbidity and mortality risks. A critical aspect of managing dengue is distinguishing between non-severe 52 and severe cases, as the latter require intensive medical intervention to prevent complications and 53 fatalities. Early identification of patients at risk of severe dengue is important for timely intervention and 54 improved patient outcomes. However, predicting which patients will progress to severe dengue remains a 55 challenge, often leading to delayed treatment and increased healthcare burden. 56 The World Health Organization (WHO) has recommended identifying severe dengue through 57 clinical assessment of warning signs such as persistent vomiting, abdominal pain, mucosal bleeding, 58 restlessness, and hepatomegaly [5]. Although these warning signs offer a practical approach for clinicians, 59 their specificity and sensitivity in accurately predicting severe dengue are limited. Studies have shown 60 that relying solely on these warning signs can result in both false positives and negatives, potentially ⁶¹leading to over- or under-treatment of patients [6-10]. The substantial burden of dengue on the healthcare 62 system, both in terms of economic cost and human suffering, underscores the need for innovative ⁶³approaches to disease diagnosis. A more accurate and efficient method for risk stratification could lead to 64 substantial improvements in patient care and resource allocation. ⁶⁵In recent years, machine learning (ML) has emerged as a powerful tool for analyzing complex 66 datasets and uncovering patterns not easily discernible by traditional methods. In the context of dengue, ⁶⁷ML models can analyze a multitude of factors beyond the established warning signs, including patient 68 demographics, laboratory results, clinical symptoms, and epidemiological data, to enhance the prediction 69 of severe disease $[11, 12]$. By leveraging ML, we aim to improve the accuracy of severe dengue

70 predictions, offering a more robust and data-driven approach to risk stratification. If successful, these ⁷¹models could transform dengue management by enabling early, accurate identification of high-risk 72 patients, ultimately leading to improved patient outcomes and reduced mortality rates. Additionally, 73 targeted intervention for high-risk patients can optimize resource allocation, ensuring critical care is 74 available to those who need it most.

⁷⁵This project specifically leverages data from Puerto Rico's Sentinel Enhanced Dengue 76 Surveillance System (SEDSS), which has detailed clinical and laboratory information on dengue cases, ⁷⁷allowing for the exploration of potential predictors of disease severity beyond the conventional warning 78 signs. In addition to exploring ML approaches, this project also aims to evaluate the performance of ⁷⁹WHO-recommended warning signs in predicting severe dengue among laboratory-confirmed cases, 80 which include both molecular (RT-PCR) and serologic (IgM ELISA) testing. By doing so, we seek to 81 bridge the gap between research and clinical practice by demonstrating the practical applications of both 82 traditional and advanced computational tools in identifying severe dengue. If our findings demonstrate 83 that ML models offer improved prediction of severe dengue compared to traditional methods, this could 84 highlight the potential for integrating advanced computational tools into public health strategies and 85 clinical protocols. For example, predictive ML models could be incorporated into clinical decision ⁸⁶support systems used in emergency departments or outpatient clinics, enabling real-time risk stratification 87 for severe dengue. This integration could help healthcare providers prioritize patients for hospitalization, 88 allocate medical resources more efficiently, and guide timely interventions to prevent complications and 89 fatalities. These tools could enable early and accurate identification of high-risk patients, improve patient 90 outcomes, and optimize resource allocation.

⁹²**Methods**

⁹³*Study population*

94 In this analysis, we used data from SEDSS, an ongoing facility-based study in Puerto Rico that 95 tracks the frequency and causes of acute febrile illness [13, 14]. Our study included data from SEDSS

122 form (Hospital Admitted Abstraction Form) to collect key clinical indicators of disease severity and 123 progression. For admitted patients, these data included information on extent and nature of hemorrhage, 124 plasma leakage (e.g., ascites and pleural and cardiac effusions), hematologic indicators of increased 125 intravascular permeability (e.g., hematocrit and serum albumin levels), additional blood pressure and 126 heart rate measures to assess shock, and indicators of severe organ involvement (e.g., liver impairment, 127 meningitis, and encephalitis) [14].

128 Dengue warning signs and severe dengue were defined by the World Health Organization [17], 129 incorporating available clinical indicators from SEDSS intake and follow-up forms and abstracted 130 inpatient medical records. Dengue warning signs were defined by abdominal pain or tenderness, 131 persistent vomiting, plasma leakage (pleural or pericardial effusion or ascites), mucosal bleeding, 132 restlessness, hemoconcentration (defined as either a hematocrit increase of \geq 20% during illness or a 133 hematocrit value \geq 20% above baseline for age and sex), or hepatomegaly. Detailed definitions for these 134 variables have been provided previously [18]. Severe dengue was defined as severe plasma leakage or 135 shock, severe bleeding, or severe organ impairment [18]. The presence and overlap of warning signs

136 among severe dengue cases were visualized using an Euler plot via the eulerr R package [19].

¹³⁸*Sample collection and laboratory procedures*

139 Blood, nasopharyngeal (NP), and oropharyngeal (OP) specimens were collected at enrollment 140 from eligible participants. Additional blood samples (serum and whole blood) were also collected during 141 the convalescent phase. Participation required providing at least one sample (blood or OP/NP swab). All 142 patients had molecular testing for dengue virus for specimens collected within 7 days of symptom onset. 143 Serologic testing was done by Immunoglobulin M (IgM) antibody capture enzyme-linked immunosorbent 144 assay (ELISA) for anti-DENV antibodies for specimens collected $>$ 3 days after symptom onset [20].

¹⁴⁶*Variables*

147 A total of 40 variables were selected based on the WHO's criteria for severe dengue, physicians' 148 clinical experience, and a review of current literature to potentially differentiate between severe and non-149 severe dengue cases [17, 18, 21-24]. These features included age group, days post onset of symptoms, 150 clinical signs and symptoms, laboratory findings, pre-existing health conditions, and dengue virus 151 serotype. Clinical symptoms included report of fever, rash, headache, myalgia, abdominal pain, chills, 152 itchy skin, eye pain, nasal discharge, cough, sore throat, persistent vomiting, diarrhea, arthralgia, arthritis, 153 back pain, calf pain, nausea, no appetite, and restlessness. Clinical signs, as observed by healthcare 154 providers, included objective fever at the time of enrollment, yellow skin (jaundice), observed bruising, 155 conjunctivitis, hepatomegaly, mucosal bleeding, pale skin, and blue lips (cyanosis). Clinical laboratory 156 findings comprised leukopenia (defined as white blood cell count $\langle 4,000/\text{mm}^3 \rangle$, the calculated value of 157 hemoconcentration (an increase in the concentration of red blood cells due to plasma loss), and dengue 158 immune status (primary or post-primary) as measured from results for anti-dengue virus immunoglobulin 159 G (IgG) on or before day 5 of illness. Pre-existing health conditions like obesity (BMI \geq 30), gastritis, 160 chronic arthritis, hypertension, chronic kidney disease, diabetes, thyroid disease, and high cholesterol 161 were also considered. Additionally, dengue virus serotype was included, coded as "unknown" for 162 probable cases identified through IgM ELISA, as serotype data was only available for confirmed reverse 163 transcription polymerase chain reaction (RT-PCR) cases. Thrombocytopenia and clinical fluid 164 accumulation were excluded from the analysis, as they generally manifest after the onset of severe disease 165 or are components of its definition, making them less useful as predictive features. This comprehensive 166 set of variables was intended to represent the multifaceted nature of factors influencing dengue infection 167 severity.

¹⁶⁹*Sensitivity analyses*

170 To further explore the performance of the models in resource-constrained settings, where 171 complete blood counts (CBCs), dengue immune status, and serotype information might not be readily 172 available, we performed sub-analyses to evaluate model robustness and applicability. The sub-analyses

173 included: 1) excluding results found on a CBC (i.e., leukopenia and hemoconcentration), 2) excluding ¹⁷⁴IgG and serotype results, and 3) excluding leukopenia, hemoconcentration, IgG, and serotype results. 175 These analyses were designed to assess how well the models could predict progression to severe dengue 176 in various clinical scenarios, particularly where access to comprehensive clinical laboratory results or 177 pathogen-specific testing might be limited. 178 To ensure the robustness of our models and account for potential confounding from co-circulating 179 arboviruses, we performed a sensitivity analysis with the highest-performing individual ML model, 180 excluding cases that tested positive for chikungunya virus (CHIKV) by either IgM or RT-PCR. This 181 analysis aimed to confirm that the predictive features for severe dengue remain consistent even in the 182 absence of CHIKV, given the potential overlap in clinical presentations between the two viruses. ¹⁸⁴*Sampling* 185 Our analysis included laboratory-confirmed dengue cases, confirmed by either molecular or 186 serologic testing, focusing on differentiating between severe and non-severe cases. Due to an imbalance 187 in the dataset, where non-severe cases were more prevalent, we used upsampling to balance the class 188 distribution. Upsampling involves increasing the number of minority class samples (severe dengue cases) 189 through duplication, which helps to prevent model bias towards the majority class and improves the ¹⁹⁰model's ability to accurately predict severe dengue cases [25]. Upsampling was done using the upSample 191 function from the caret package in R $[26]$. Following upsampling, the dataset was divided into training 192 and testing sets using a 70/30 split: 70% of the data was allocated for training the models, while the 193 remaining 30% was reserved for testing. This partitioning ensured that the models were trained on a 194 substantial portion of the data while retaining a sufficient amount for unbiased evaluation. ¹⁹⁶*Machine learning models*

197 An initial logistic regression (LR) model served as a baseline simple model to explore the 198 relationship between potential predictors and the outcome of severe dengue. Stepwise selection,

199 implemented using the stepAIC function from the MASS package in R $[27]$, was used to iteratively add 200 or remove variables to identify the optimal model with the lowest Akaike Information Criterion. This 201 approach balances model complexity and goodness-of-fit by selecting variables that contribute 202 significantly to the model. The final logistic regression model, derived from stepwise selection, was 203 evaluated on both the training and testing sets. 204 In addition, we used nine ML methods to predict severe dengue and analyze feature importance. 205 A comprehensive selection of models was used to leverage different strengths, enhance predictive 206 performance, and provide a nuanced understanding of the factors contributing to severe dengue. The 207 algorithms used include Decision Trees (DT), K-Nearest Neighbors (KNN), Naïve Bayes, Support Vector 208 Machines (SVM), Artificial Neural Networks (ANN), Adaptive Boosting (AdaBoost), Categorical 209 Boosting (CatBoost), Light Gradient Boosting Machine (LightGBM), and eXtreme Gradient Boosting ²¹⁰(XGBoost). DTs create a tree-like structure to make predictions by recursively splitting the data based on 211 feature values [28]. KNNs predict the class of a data point by considering the majority class of its closest 212 neighbors in the feature space [29]. Naïve Bayes is a probabilistic classifier that applies Bayes' theorem, 213 assuming independence between predictors [30]. SVMs identify the optimal hyperplane to separate 214 classes, making them effective for high-dimensional data [31]. ANNs are inspired by biological neural 215 networks and consist of interconnected nodes that can capture complex patterns [32]. AdaBoost, 216 CatBoost, LightGBM, and XGBoost are ensemble methods that combine multiple weak learners to 217 improve predictive performance [33, 34]. AdaBoost adjusts weights to focus on difficult-to-predict 218 instances, CatBoost handles categorical features effectively, LightGBM is efficient with large datasets 219 due to its leaf-wise tree growth, and XGBoost uses regularization techniques to prevent overfitting, 220 enhancing accuracy and robustness [33-35]. 221 The hyperparameters (model-specific settings, such as learning rate, maximum tree depth, or 222 number of estimators) for each ML model were carefully tuned using a grid search strategy to optimize

223 performance. The area under the receiver operating characteristic curve (AUC-ROC) was used as the

224 optimization metric, ensuring a focus on maximizing classification performance. We used 5-fold cross-

225 validation during model training to enhance robustness and mitigate overfitting. Specific details of the 226 grid search strategy and parameters included in each model are provided in Table S1. 227 The following R packages were used for model implementation: rpart [36] for DT, e1071 [37] for 228 Naïve Bayes and SVM, caret [26] for KNN, nnet [38] for ANN, keras [39] for DNN, ada [40] for 229 AdaBoost, catboost [41] for CatBoost, lightgbm [42] for LightGBM, and xgboost [43] for XGBoost. All 230 analyses were done using R version $4.4.0$ [44]. 231 ²³²*Ensemble model* 233 To leverage the predictive power of multiple ML algorithms, we used an ensemble learning ²³⁴approach with a stacked generalization framework. This method combines the strengths of various 235 individual models to improve overall predictive performance and robustness. We used predictions from 236 LR and the nine different ML models as base learners in our ensemble. Specifically, we used a logistic 237 regression model as the meta-learner to combine the outputs of the base models. This approach allows the 238 meta-model to learn the optimal combination of base models' predictions. To improve the performance of 239 the meta-model, we again used stepwise selection with the stepAIC function from the MASS package 240 [27]. ²⁴¹Pearson correlation coefficients were calculated to measure the linear correlation between the 242 predictions of the ML models. This analysis helps determine whether the models are making similar ²⁴³predictions for severe dengue, potentially reflecting the selection of similar variables and patterns across 244 the models. The results were visualized in a heatmap using ggplot2 $[45]$. 245
2 ²⁴⁶*Performance evaluation* 247 Model performance for each ML model and the meta-model was evaluated on both the training 248 and testing sets using AUC-ROC as the primary performance metric. AUC-ROC is an aggregate measure 249 of performance across all possible classification thresholds, providing a comprehensive assessment of the

250 model's ability to distinguish between classes. We used the DeLong method to calculate the confidence 251 intervals for the AUC-ROC to ensure accurate estimation of the model's performance [46]. 252 The performance of the ensemble model was further evaluated using several metrics, including 253 accuracy, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), F1 254 score, and Cohen's kappa. These metrics provide a comprehensive view of the model's performance, 255 capturing both the ability to correctly classify severe dengue cases and the overall agreement between 256 predicted and actual classifications. ²⁵⁸*Feature importance*

259 Feature importance was calculated for each ML model to quantify the contribution of each 260 variable to the model's predictive accuracy. This approach enables the identification of the most 261 influential features, which enhances our understanding of the factors driving the predictions for severe 262 dengue. Feature importance was assessed for both the 40-variable feature set and a subset excluding ²⁶³CBCs, IgG, and serotype results. Different methods were applied across the ML algorithms to determine ²⁶⁴feature importance. For ensemble-based methods, including XGBoost, LightGBM, and CatBoost, feature 265 importance was calculated using the Gain metric, which measures the contribution of each feature to the 266 model's decision-making process. Gain represents the improvement in the model's accuracy brought by a 267 feature, with higher values indicating greater importance. For XGBoost, LightGBM, and CatBoost, we 268 used the xgb.importance, lgb.importance, and catboost.get_feature_importance functions from the 269 xgboost [43], lightgbm [42], and catboost [41] packages, respectively.

270 Permutation importance was applied to assess feature importance for KNN, Naive Bayes, and ²⁷¹ANN. This method involves randomly shuffling feature values and measuring the subsequent decline in 272 model performance. A substantial decrease in accuracy indicates a highly influential feature. For DT, 273 feature importance was determined by the reduction in impurity (Gini index or entropy) achieved by 274 splitting data based on that feature. AdaBoost assigned importance to features based on their contribution 275 to correcting errors in subsequent models, with higher weights indicating greater influence. For SVM,

276 feature importance was derived from the absolute value of the model coefficients. The magnitude of these 277 coefficients reflects the influence of each feature on the decision boundary, with larger coefficients 278 indicating greater importance. 279 We also calculated and plotted SHapley Additive exPlanations (SHAP) values for the top three 280 performing models based on AUC-ROC. SHAP values provide a nuanced measure of each feature's 281 contribution to the prediction of severe dengue cases, enabling a deeper understanding of model decision-282 making. Positive SHAP values indicate a higher likelihood of severe dengue, whereas negative values 283 suggest a protective effect. The SHAP approach is particularly valuable as it allows for the decomposition 284 of the prediction into individual feature contributions, offering a clear interpretation of how different 285 variables influence the model's predictions. ²⁸⁷*Post-hoc variable reduction analysis* 288 To assess the predictive performance of a simplified variable set, we conducted a post-hoc 289 analysis using the ML model that achieved the highest AUC. This analysis aimed to identify the ²⁹⁰minimum number of features needed to maintain high accuracy. We began with the top features identified 291 through SHAP values in the original 40-variable analysis, adding one feature at a time, starting with the 292 highest-ranking. At each step, we evaluated the AUC-ROC to determine the impact of including 293 additional features. The goal was to develop a more streamlined model that remains feasible and 294 interpretable, especially in clinical settings with limited diagnostic resource. ²⁹⁶*Diagnostic accuracy of warning signs* 297 In addition to ML, we evaluated the diagnostic accuracy of individual warning signs for 298 identifying severe dengue cases. The performance of each warning sign was assessed using sensitivity, 299 specificity, PPV, NPV, and AUC-ROC. Sub-analyses assessed the performance of warning signs by

300 dengue serotype and immune status. Dengue serotype was determined via RT-PCR, whereas immune

301 status was classified based on IgG antibody results in the first 5 days after illness onset (primary: IgG;

353 emphasizing similar variables in their predictive processes. In contrast, weaker correlations were observed

³⁷⁹*Feature importance*

⁴⁰⁴**Discussion**

405 Our study underscores the potential of ML models, particularly gradient boosting algorithms, to 406 outperform traditional warning signs in predicting severe dengue. This improved predictive ability could 407 transform clinical decision-making, enabling earlier and more accurate identification of high-risk patients, 408 thereby improving outcomes in dengue-endemic regions like Puerto Rico.

⁴⁰⁹Hemoconcentration, days post symptom onset, and leukopenia emerged as the most important 410 features across multiple ML models, aligning with their known relevance in dengue prognosis [47-49]. 411 Hemoconcentration, which reflects plasma leakage through an increased red blood cell concentration, was 412 consistently highlighted as a top predictor by CatBoost, XGBoost, LightGBM, and several other 413 algorithms. Days post symptom onset is a crucial temporal marker, likely capturing the dynamic nature of 414 disease as cases often progress to the critical phase of dengue (when severe disease occurs) 3–7 days after ⁴¹⁵symptom onset. Leukopenia, or low white blood cell count, often reflects the body's response to viral ⁴¹⁶infections, including dengue. In addition, pale skin, age group, and clinical warning signs such as 417 restlessness, abdominal pain, and persistent vomiting were identified as key predictors of severe dengue 418 progression. The variability in feature importance across models emphasizes the complexity of severe 419 dengue prediction, highlighting the need for tailored approaches that account for both individual patient 420 characteristics and disease progression.

421 Our analysis highlights the strong predictive performance of gradient boosting algorithms— ⁴²²CatBoost, XGBoost, and LightGBM—with AUC values above 94%, reflecting their ability to capture ⁴²³complex, non-linear patterns in clinical data [35, 50-52]. Despite this high predictive accuracy, the 424 interpretability of these models remains a limitation in clinical settings, where transparency in decision-425 making is critical for trust and practical use [53-55]. Compared to simpler models like LR, which offers 426 straightforward interpretations of how each variable influences severe dengue risk, gradient boosting 427 algorithms can be challenging to interpret. This trade-off between high performance and interpretability ⁴²⁸suggests that ML models may be most useful as supplementary tools for alerting clinicians to high-risk 429 cases, rather than as standalone decision aids.

430 In contrast, simpler models like Naïve Bayes, Decision Trees, and KNN showed weaker 431 correlations and lower AUC values, reflecting their limitations in capturing data complexity. The ⁴³²ensemble model, achieving the highest AUC of 97.7%, demonstrates the added value of combining 433 multiple ML algorithms to enhance predictive accuracy, with high sensitivity and specificity, making it ⁴³⁴particularly useful in resource-limited settings [56, 57]. Additionally, the exclusion of immune status and ⁴³⁵serotype data had minimal impact on model performance, indicating these variables are not essential for 436 accurate prediction in this context. The high NPV across models suggests that ML tools can still be 437 valuable for identifying low-risk patients who may not require intensive monitoring. In these cases, the 438 ML model's recommendation could serve as an early discharge or outpatient management decision-439 support mechanism, further optimizing healthcare resource allocation. ⁴⁴⁰The post-hoc variable reduction analysis demonstrated that a streamlined set of 20 variables 441 achieved strong predictive accuracy (AUC of 96.5%), close to the full 40-variable model. This reduced ⁴⁴²set offers a balance between interpretability and performance, making it more practical for clinical ⁴⁴³application, particularly in settings with limited diagnostic resources. By focusing on essential ⁴⁴⁴predictors—such as hemoconcentration, days post onset, leukopenia, and key symptoms—this approach ⁴⁴⁵prioritizes feasibility and interpretability, even if it means a modest sacrifice in predictive power. For 446 added clinical utility, LR could complement ML approaches by further refining and validating the 447 reduced variable set with interpretable odds ratios, enabling clinicians to apply these findings more 448 confidently in practice [58].

⁴⁴⁹Traditional warning signs showed both strengths and limitations. Abdominal pain and restlessness 450 were the most sensitive indicators, consistent with other studies [6, 9], yet their low specificities limit 451 their utility. Conversely, markers like hepatomegaly and hemoconcentration had high specificity but low 452 sensitivity. Combining multiple warning signs improved specificity while maintaining high sensitivity, 453 yielding the highest AUC among tested combinations. In contrast, gradient boosting ML algorithms ⁴⁵⁴offered a more balanced approach with high sensitivity and specificity, crucial for accurate risk ⁴⁵⁵stratification in clinical settings. Our findings align with a recent study where an 8-gene XGBoost model

456 outperformed clinical warning signs, significantly improving negative predictive power and 457 demonstrating strong generalizability across patient cohorts [54]. Although our models focus on 458 demographic and clinical features, the integration of gene expression data presents an intriguing avenue 459 for future exploration [54, 55]. ⁴⁶⁰This study has several limitations. First, these ML models need to be re-fitted to different ⁴⁶¹variables and populations to ensure accuracy across various settings. Second, the relatively small dataset ⁴⁶²increases the risk of overfitting, potentially affecting the models' robustness and generalizability. Third, ⁴⁶³the prevalence of DENV-1 cases from the 2012-2013 outbreak may limit the models' applicability to 464 other periods, regions, populations, age groups, or serotypes. Fourth, the models were developed using 465 data from the SEDSS, where inclusion criteria required febrile illness, potentially limiting generalizability 466 to broader populations. Fifth, due to limited sample sizes for serotypes and immune statuses, we could not 467 conduct ML analyses for these subgroups; future studies with larger datasets are needed to validate ⁴⁶⁸findings. Sixth, there is a potential limitation related to the inclusion of false negatives—SEDSS cases 469 who may have later presented to a non-SEDSS facility with severe disease—although this is considered 470 unlikely given typical healthcare-seeking behaviors. Seventh, the SEDSS data's robustness may not 471 accurately reflect real-world conditions, where datasets are often sparse, contain free-text fields, or have ⁴⁷²incomplete information, potentially affecting model performance. Eighth, dengue and severe dengue are 473 often underdiagnosed and underreported, which could impact model results; however, our findings likely 474 represent a conservative estimate when accounting for underreporting. Finally, implementing ML models 475 in clinical practice may require computational resources and infrastructure not available in all settings, 476 particularly in low-resource environments where dengue is endemic.

⁴⁷⁸**Conclusions**

479 Although traditional warning signs are essential in clinical practice, their low specificity often 480 leads to high hospitalization rates, potentially overwhelming healthcare systems. Our findings suggest 481 that ML models, particularly gradient boosting algorithms, offer a more effective approach by integrating

- ⁴⁸²multiple variables and capturing complex interactions, thereby improving specificity while maintaining
- ⁴⁸³sensitivity. Implementing these models in clinical decision-making could help identify patients at highest
- ⁴⁸⁴risk for progression to severe dengue, reducing unnecessary hospitalizations and easing healthcare
- 485 burdens. Although resource constraints may limit direct ML implementation in some settings, platforms
- 486 like SEDSS can still leverage ML techniques to identify key predictors of severe disease. This approach
- 487 can optimize patient care by prioritizing the most critical predictors, even in low-resource environments
- 488 where advanced ML algorithms may not be feasible.
- $\ddot{}$

⁴⁹⁰**Abbreviations**

- 491 AdaBoost: Adaptive Boosting
- ⁴⁹²AFI: acute febrile illness
- 493 ANN: Artificial Neural Networks
- ⁴⁹⁴AUC-ROC: area under the receiver operating characteristic curve
- 495 CatBoost: Categorical Boosting
- 496 CBC: complete blood count
- 497 CHIKV: chikungunya virus
- 498 CSPF: convalescent sample processing form
- 499 CEMI: Centro de Emergencia y Medicina Integrada
- 500 CIF: case investigation form
- 501 CMESL: Centro Médico Episcopal San Lucas
- 502 DT: Decision Trees
- ⁵⁰³ELISA: enzyme-linked immunosorbent assay
- 504 HESL: Hospital Episcopal San Lucas
- 505 KNN: K-Nearest Neighbors
- 506 LightGBM: Light Gradient Boosting Machine
- ⁵⁰⁷LR: logistic regression

- ⁵⁰⁸ML: machine learning
- 509 NPV: negative predictive value
- 510 PPV: positive predictive value
- 511 RT-PCR: reverse transcription polymerase chain reaction
- 512 SEDSS: Sentinel Enhanced Dengue Surveillance System
- 513 SHAP: SHapley Additive exPlanations
- 514 SVM: Support Vector Machines
- 515 XGBoost: eXtreme Gradient Boosting
- 516 WHO: World Health Organization

⁵¹⁷**Declarations**

- ⁵¹⁸**Ethics approval and consent to participate:** The Institutional Review Boards at the Centers for Disease
- 519 Control and Prevention (CDC), Auxilio Mutuo, and Ponce Medical School Foundation approved the
- 520 SEDSS study protocols 6214, and 120308-VR/2311173707, respectively. Written consent to participate
- 521 was obtained from all adult participants and emancipated minors. For minors aged 14 to 20 years, written
- 522 consent was obtained, and for those aged 7 to 13 years, parental written consent and participant assent
- 523 were obtained.
- ⁵²⁴**Consent for publication:** Not applicable.
- ⁵²⁵**Availability of data and materials:** Data cannot be shared publicly because data cannot be deidentified
- 526 at the granular level of analyses performed. Data are available from the CDC management team (contact:
- 527 dengue@cdc.gov) for researchers who meet the criteria for access to confidential data.
- ⁵²⁸**Competing interests:** The authors declare no conflict of interests.
- ⁵²⁹**Funding**: This research was funded by Centers for Disease Control and Prevention, grant
- 530 numbers U01CK000473 and U01CK000580 (VRA).
- ⁵³¹**Authors' contributions:** Conception and design of the study: ZJM, MBT, and JMW. Acquisition of data:
- 532 VR. Analysis and interpretation of data: ZJM. Drafting the article: ZJM. Revising the article critically for
- 533 important intellectual content: ZJM, DR, MBT, VR, GP, LEA, and JMW. All authors have made
- 534 substantial contributions to the study. All authors read and approved the final manuscript.
- ⁵³⁵**Acknowledgements:** Not applicable.
- ⁵³⁶**Disclaimer:** The findings and conclusions in this report are those of the authors and do not necessarily
- 537 represent the official position of the US Centers for Disease Control and Prevention.

References

- 539 1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS,
- Hoen AG, Sankoh O *et al*: **The global distribution and burden of dengue**. *Nature* 2013,
- **496**(7446):504-507.
- 2. **Global, regional, and national age-sex-specific mortality for 282 causes of death in 195**
- **countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease**
- **Study 2017**. *Lancet* 2018, **392**(10159):1736-1788.
- 545 3. Ryff KR, Rivera A, Rodriguez DM, Santiago GA, Medina FA, Ellis EM, Torres J, Pobutsky A,
- 546 Munoz-Jordan J, Paz-Bailey G, Adams LE: **Epidemiologic Trends of Dengue in U.S.**
- **Territories, 2010-2020**. *MMWR Surveill Summ* 2023, **72**(4):1-12.
- 4. Thayer MB, Marzan-Rodriguez M, Torres Aponte J, Rivera A, Rodriguez DM, Madewell ZJ,
- Rysava K, Paz-Bailey G, Adams LE, Johansson MA: **Dengue epidemic alert thresholds: A tool for surveillance and epidemic detection**. *medRxiv* 2024:2024.2010.2022.24315684.
- 5. **WHO Guidelines Approved by the Guidelines Review Committee**. In: *Dengue: Guidelines for*
- *Diagnosis, Treatment, Prevention and Control: New Edition.* edn. Geneva: World Health
- 553 Organization, Copyright © 2009, World Health Organization.; 2009.
- 6. Ahmad MH, Ibrahim MI, Mohamed Z, Ismail N, Abdullah MA, Shueb RH, Shafei MN: **The**
- **sensitivity, specificity and accuracy of warning signs in predicting severe dengue, the severe**
- **dengue prevalence and its associated factors**. *International Journal of Environmental Research*
- *and Public Health* 2018, **15**(9):2018.
- 7. Narvaez F, Gutierrez G, Pérez MA, Elizondo D, Nuñez A, Balmaseda A, Harris E: **Evaluation of the traditional and revised WHO classifications of dengue disease severity**. *PLoS neglected*
- *tropical diseases* 2011, **5**(11):e1397.
- 8. Macedo GA, Gonin MLC, Pone SM, Cruz OG, Nobre FF, Brasil P: **Sensitivity and specificity of**
- **the World Health Organization dengue classification schemes for severe dengue assessment**
- **in children in Rio de Janeiro**. *PloS one* 2014, **9**(4):e96314.

- *Hygiene* 2023, **108**(1):107.
- 591 17. **Handbook for clinical management of dengue**
- 592 [https://www.who.int/publications/i/item/9789241504713]
- 18. Paz-Bailey G, Sánchez-González L, Torres-Velasquez B, Jones ES, Perez-Padilla J, Sharp TM,
- Lorenzi O, Delorey M, Munoz-Jordan JL, Tomashek KM *et al*: **Predominance of Severe Plasma**
- **Leakage in Pediatric Patients With Severe Dengue in Puerto Rico**. *The Journal of Infectious*
- *Diseases* 2022, **226**(11):1949-1958.
- 19. **eulerr: Area-Proportional Euler and Venn Diagrams with Ellipses** [https://cran.r-
- 598 project.org/web/packages/eulerr/index.html
- 20. Tomashek KM, Lorenzi OD, Andújar-Pérez DA, Torres-Velásquez BC, Hunsperger EA, Munoz-

Jordan JL, Perez-Padilla J, Rivera A, Gonzalez-Zeno GE, Sharp TM *et al*: **Clinical and**

- **epidemiologic characteristics of dengue and other etiologic agents among patients with**
- **acute febrile illness, Puerto Rico, 2012-2015**. *PLoS Negl Trop Dis* 2017, **11**(9):e0005859.
- 21. Tsheten T, Clements ACA, Gray DJ, Adhikary RK, Furuya-Kanamori L, Wangdi K: **Clinical**
- **predictors of severe dengue: a systematic review and meta-analysis**. *Infect Dis Poverty* 2021, **10**(1):123.
- 22. Sangkaew S, Ming D, Boonyasiri A, Honeyford K, Kalayanarooj S, Yacoub S, Dorigatti I,
- Holmes A: **Risk predictors of progression to severe disease during the febrile phase of**
- **dengue: a systematic review and meta-analysis**. *Lancet Infect Dis* 2021, **21**(7):1014-1026.
- 23. Khan MAS, Al Mosabbir A, Raheem E, Ahmed A, Rouf RR, Hasan M, Alam FB, Hannan N,
- Yesmin S, Amin R *et al*: **Clinical spectrum and predictors of severity of dengue among**
- **children in 2019 outbreak: a multicenter hospital-based study in Bangladesh**. *BMC Pediatr*
- 2021, **21**(1):478.
- 24. Yuan K, Chen Y, Zhong M, Lin Y, Liu L: **Risk and predictive factors for severe dengue infection: A systematic review and meta-analysis**. *PLoS One* 2022, **17**(4):e0267186.

- 25. Werner de Vargas V, Schneider Aranda JA, Dos Santos Costa R, da Silva Pereira PR, Victória
- Barbosa JL: **Imbalanced data preprocessing techniques for machine learning: a systematic**
- **mapping study**. *Knowl Inf Syst* 2023, **65**(1):31-57.
- 26. **caret: Classification and Regression Training** [https://cran.r-
- 619 project.org/web/packages/caret/index.html]
- 27. **MASS: Support Functions and Datasets for Venables and Ripley's MASS** [https://cran.r-
- 621 project.org/web/packages/MASS/index.html]
- 28. Kotsiantis SB: **Decision trees: a recent overview**. *Artificial Intelligence Review* 2013, **39**:261-
- 623 283.
- 29. Peterson LE: **K-nearest neighbor**. *Scholarpedia* 2009, **4**(2):1883.
- 30. Webb GI, Keogh E, Miikkulainen R: **Naïve Bayes**. *Encyclopedia of machine learning* 2010, **15**(1):713-714.
- 31. Hearst MA, Dumais ST, Osuna E, Platt J, Scholkopf B: **Support vector machines**. *IEEE Intelligent Systems and their applications* 1998, **13**(4):18-28.
- 32. Aggarwal CC: **Neural networks and deep learning**, vol. 10: Springer; 2018.
- 33. Schapire RE: **The boosting approach to machine learning: An overview**. *Nonlinear estimation*
- *and classification* 2003:149-171.
- 34. Bentéjac C, Csörgő A, Martínez-Muñoz G: **A comparative analysis of gradient boosting algorithms**. *Artificial Intelligence Review* 2021, **54**:1937-1967.
- 35. Khan AA, Chaudhari O, Chandra R: **A review of ensemble learning and data augmentation**
- **models for class imbalanced problems: Combination, implementation and evaluation**.
- *Expert Systems with Applications* 2024, **244**:122778.
- 36. **rpart: Recursive Partitioning and Regression Trees** [https://cran.r-
- 638 project.org/web/packages/rpart/index.html]
- 37. **e1071: Misc Functions of the Department of Statistics, Probability Theory Group**
- **(Formerly: E1071), TU Wien** [https://cran.r-project.org/web/packages/e1071/index.html]

- 38. **nnet: Feed-Forward Neural Networks and Multinomial Log-Linear Models** [https://cran.r-
- project.org/web/packages/nnet/index.html]
- 39. **keras: R Interface to 'Keras'** [https://cran.r-project.org/web/packages/keras/index.html]
- 40. **ada: The R Package Ada for Stochastic Boosting** [https://cran.r-
- 645 project.org/web/packages/ada/index.html
- 41. Prokhorenkova L, Gusev G, Vorobev A, Dorogush AV, Gulin A: **CatBoost: unbiased boosting**
- **with categorical features**. *Advances in neural information processing systems* 2018, **31**.
- 42. **lightgbm: Light Gradient Boosting Machine** [https://cran.r-
- 649 project.org/web/packages/lightgbm/index.html]
- 43. **xgboost: Extreme Gradient Boosting** [https://cran.r-
- project.org/web/packages/xgboost/index.html]
- 44. **R: A language and environment for statistical computing.**
- 45. Wickham H: **ggplot2**. *Wiley interdisciplinary reviews: computational statistics* 2011, **3**(2):180- 654 185.
- 46. DeLong ER, DeLong DM, Clarke-Pearson DL: **Comparing the areas under two or more**
- **correlated receiver operating characteristic curves: a nonparametric approach**. *Biometrics*
- 1988, **44**(3):837-845.
- 47. Lee IK, Huang CH, Huang WC, Chen YC, Tsai CY, Chang K, Chen YH: **Prognostic Factors in**
- **Adult Patients with Dengue: Developing Risk Scoring Models and Emphasizing Factors**
- **Associated with Death** ≤**7 Days after Illness Onset and** ≤**3 Days after Presentation**. *J Clin*
- *Med* 2018, **7**(11).
- 48. Wakimoto MD, Camacho LA, Guaraldo L, Damasceno LS, Brasil P: **Dengue in children: a**
- **systematic review of clinical and laboratory factors associated with severity**. *Expert Rev Anti*
- *Infect Ther* 2015, **13**(12):1441-1456.

- ⁶⁹¹57. Dean NE, Pastore YPA, Madewell ZJ, Cummings DAT, Hitchings MDT, Joshi K, Kahn R,
- 692 Vespignani A, Halloran ME, Longini IM, Jr.: **Ensemble forecast modeling for the design of**
- ⁶⁹³**COVID-19 vaccine efficacy trials**. *Vaccine* 2020, **38**(46):7213-7216.
- ⁶⁹⁴58. Ho TS, Weng TC, Wang JD, Han HC, Cheng HC, Yang CC, Yu CH, Liu YJ, Hu CH, Huang CY
- ⁶⁹⁵*et al*: **Comparing machine learning with case-control models to identify confirmed dengue**
- ⁶⁹⁶**cases**. *PLoS Negl Trop Dis* 2020, **14**(11):e0008843.
- 697

⁶⁹⁸**Figure Titles and Legends**

- ⁶⁹⁹**Figure 1**. Euler plot of proportion of severe dengue cases with each warning sign, Sentinel Enhanced
- 700 Dengue Surveillance System, Puerto Rico, 2012–2024.
- ⁷⁰¹**Figure 2**. Pearson's correlation of predictions between machine learning models, Sentinel Enhanced
- 702 Dengue Surveillance System, Puerto Rico, 2012–2024. Pearson correlation coefficients measure the linear
- 703 agreement between the predictions of different machine learning models. Higher values indicate similar
- 704 prediction patterns across models, suggesting that models are identifying similar cases as severe dengue.
- 705 Darker colors represent higher correlations.
- ⁷⁰⁶**Figure 3**. Forest plot of AUC values for Decision Trees (DT), K-Nearest Neighbors (KNN), Naïve Bayes,
- 707 Support Vector Machines (SVM), Artificial Neural Networks (ANN), Adaptive Boosting (AdaBoost),
- 708 Categorical Boosting (CatBoost), Light Gradient Boosting Machine (LightGBM), eXtreme Gradient
- 709 Boosting (XGBoost), and ensemble models for a 40-variable feature set and subsets excluding CBCs,
- 710 IgG, and serotype results, Sentinel Enhanced Dengue Surveillance System, Puerto Rico, 2012–2024.
- 711 DeLong method was used to obtain the 95% confidence intervals for the AUC-ROC. CBC = complete
- 712 blood count, IgG = immunoglobulin G, AUC-ROC = area under the receiver operating characteristic
- 713 curve.

⁷¹⁴**Figure 4.** SHapley Additive exPlanations (SHAP) values for the 40 Features in CatBoost, Sentinel

- ⁷¹⁵Enhanced Dengue Surveillance System, Puerto Rico, 2012–2024. SHAP values measure each feature's
- 716 contribution to the prediction of severe dengue in the CatBoost model. Positive SHAP values indicate a
- ⁷¹⁷higher likelihood of severe dengue, while negative values suggest a lower likelihood (or protective

718 effect). Each dot represents a single case, with its horizontal position showing the SHAP value, reflecting

719 the strength and direction of the feature's impact. The color of the dots indicates the actual feature value

- 720 for each case. For most features, values are binary $(0 \text{ or } 1)$, representing presence or absence (e.g., rash or
- 721 no rash). For age group, the scale ranges from 0 to 7, with 0 indicating the youngest age group \langle / year)
- 722 and 7 indicating the oldest age group $(\geq 50 \text{ years})$. An example interpretation: if' 'persistent vomiting' has
- 723 a positive SHAP value and the dot is green (value $= 1$), it indicates that the presence of persistent

- 724 vomiting strongly increases the likelihood of severe dengue for that case. The mean SHAP values shown
- 725 on the right represent the average absolute impact of each feature across all cases, indicating the overall

726 importance of that feature in the model's predictions.

- ⁷²⁷**Figure 5.** Iterative improvement in area under the curve (AUC) with additional variables in CatBoost
- 728 model for severe dengue prediction, Sentinel Enhanced Dengue Surveillance System, Puerto Rico, 2012–
- ⁷²⁹2024. This figure shows the change in AUC as top-performing variables are sequentially added to the
- 730 CatBoost model. Starting with the highest-impact feature, "Days post onset," each subsequent model
- 731 includes one additional variable in the order of their mean SHAP values. The combinations of variables
- 732 and their AUC, along with 95% confidence intervals, are shown to demonstrate the predictive gain with
- 733 each added variable.

Table 1. Demographic and clinical characteristics of participants with laboratory-confirmed dengue (RT-PCR and IgM ELISA) by severity, Sentinel Enhanced Dengue Surveillance System, Puerto Rico, 2012–2024.

^p-values were calculated using either the chi-square test or Fisher's exact test, as appropriate, based on the sample sizes in each category.

Table 2. Performance of warning signs for predicting severe dengue (n=1708), Sentinel Enhanced Dengue Surveillance System, Puerto Rico, 2012–2024.

AUC-ROC: area under receiver operating characteristic curve.

 $\overline{1}$

I

Variable Combinations